

1 Artical

2 **Praeruptorin A inhibits cervical cancer HeLa cell growth and invasion by**
3 **suppressing MMP-2 expression and ERK1/2 signaling**

4 Min-Hua Wu^{1,2}, Chia-Liang Lin³, Hui-Ling Chiou⁴, Shun-Fa Yang^{1,5}, Yi-Hsien
5 Hsieh^{3,6,7*}, Chung-Jung Liu^{8,9,*}

6 ¹Institute of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan;
7 3150@ccgh.com.tw (M.-H. W); ysf@csmu.edu.tw (S.-F. Y)

8 ²Department of Laboratory, Chung-Kang Branch , Cheng-Ching General Hospital,
9 Taichung, 40764, Taiwan ; 3150@ccgh.com.tw

10 ³Institute of Biochemistry, Microbiology and Immunology, Chung Shan Medical
11 University, 40201, Taiwan; hiking003@hotmail.com

12 ⁴School of Medical Laboratory and Biotechnology, Chung Shan Medical University,
13 Taichung, 40201, Taiwan; hlchiou@csmu.edu.tw

14 ⁵Department of Medical Research, Chung Shan Medical University Hospital, Taichung,
15 40201, Taiwan; ysf@csmu.edu.tw.

16 ⁶Department of Biochemistry, School of Medicine, Chung Shan Medical University,
17 Taichung, 40201, Taiwan; hyhsien@csmu.edu.tw

18 ⁷Clinical laboratory, Chung Shan Medical University Hospital, Taichung, 40201,
19 Taiwan; hyhsien@csmu.edu.tw

20 ⁸Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical
21 University Hospital, Kaohsiung, 80708, Taiwan; pinkporkkimo@yahoo.com.tw

22 ⁹Center for Stem Cell Research, Kaohsiung Medical University, Kaohsiung, 80708,
23 Taiwan; pinkporkkimo@yahoo.com.tw

24 *Correspondence: hyhsien@csmu.edu.tw (Y.-H. H); pinkporkkimo@yahoo.com.tw

25 (C. -J. L)
26 Tel.: +886-4-2473-9595 (ext. 11673) (Y.-H. H); +886-7-3121101 (ext. 7450) (C. -J.
27 L)
28 Fax: +886-4-23248110 (Y.-H. H)

29 ABSTRACT

30 Praeruptorin A(PA), a naturally existing pyranocoumarin, is isolated from the dried
31 root of *Peucedanum praeruptorum* Dunn. So far the anti-cancer effect and molecular
32 mechanism behind Praeruptorin A action in human cervical cancer HeLa cells remain
33 unknown. In the present study, we find that PA reduces cell proliferation and colony
34 formation of human cervical cancer HeLa cells through inducing cell cycle arrest at
35 G0/G1 phase. PA-upregulated p21 and p27 proteins are observed, accompanied with
36 inhibition of cyclin D1 and S-phase kinase-associated *protein 2*(Skp2) proteins
37 expression. PA could significantly inhibit migration and invasion of human HeLa cells.
38 Meanwhile, PA significantly reduces invasive protein expression of matrix
39 metalloproteinase-2 (MMP-2), and increases protein expression of tissue inhibitor of
40 metalloproteinase-2 (TIMP-2). PA is observed to possess the capacity in suppressing
41 ERK1/2 activation. PD98059 (ERK specific inhibitor) significantly enhances PA-
42 induced downregulation of MMP-2 expression, and upregulation of TIMP-2 expression.
43 Moreover, we found that PA treatment notably inhibits 12-O-tetradecanoylphorbol-13-
44 acetate(TPA)-upregulated ERK1/2 activation, MMP-2 expression, cellular migration
45 and invasion in human HeLa cells. Taken together, these findings are the first to
46 demonstrate the anti-cancer activity of PA, which may act as a promising therapeutic
47 agent for the treatment of human cervical cancer.

48 **Keywords:** Praeruptorin A, human cervical cancer, ERK, Invasion, MMP-2, TIMP-2

49 1. Introduction

50 Cervical cancer is the second most frequent type of gynecologic cancer worldwide
51 with 530,000 new cases in 2012, and 300,000 deaths from cervical cancer in 2015.
52 Cervical cancer patients mainly die from disease recurrence or progression despite the
53 advanced chemotherapeutic treatments [1]. The high lethality of cervical cancer results
54 from its resistance to available chemotherapy and rare adaptability to radiotherapy [1],
55 which thus leaves cervical cancer with no effective therapy and the very poor prognosis.
56 Metastasis of cervical cancer to other sites such as lymph nodes, lung, bone, liver, and
57 bowel [2-6] are the critical factors, which leads to the high mortality in cervical cancer
58 patients. So far surgical tumor resection represents the effective therapeutic method for
59 cervical cancer patients due to unsuccessful chemotherapy. Therefore, the novel
60 potential strategy for inhibiting cell growth and metastasis in cervical cancer needs to
61 be explored.

62 Metastasis of cancer is the major cause leading to the poor clinical outcomes and
63 the high mortality. Metastasis is a complex process that includes cell adhesion,
64 migration, invasion and the proteolytic degradation of the extracellular matrix (ECM).
65 ECM degradation by extracellular proteinases contributes to the progress of tumor cell
66 invasion and metastasis [7]. Matrix metalloproteinases (MMPs) belongs to the
67 proteolytic proteinase systems which are primarily responsible for ECM degradation *in*
68 *vivo* [7-8]. MMPs are the zinc-containing enzymes that include interstitial collagenases,
69 gelatinases, stromelysin, matrilysin, metalloelastase, and membrane-type MMPs [9,10].
70 MMP-2 and MMP-9 is shown to possess the important role in the malignant
71 development of cervical cancer in animal models and patients[11-13]. MMP activity is
72 closely regulated by the physiological inhibitors, tissue Inhibitor of metalloproteinase
73 (TIMPs), through modification in the activation and stability of MMPs [14].

74 The compounds from plants are being examined for their efficacy for the clinical

75 treatment of many cancers that are in the screening program for detection of early
76 cancer lesions. Herbal medicine or natural food used to treat different types of cancers
77 for cancer therapy are revealed to might possess the capacity of the synergistic effects
78 in the treatment combining antitumor agents, or might replace the conventional
79 chemotherapy [15]. Praeruptorin A(PA), a major bioactive pyranocoumarin, is isolated
80 from the dried root of *Peucedanum praeruptorum* DUNN (*P. praeruptorum*). Many
81 pharmacological studies reveal that the extract of *P. praeruptorum* might possess a wide
82 variety of activities such as anti-inflammation, anti-microbiome, neuroprotection and
83 anti-cancer [15]. PA is reported to possess the cytotoxicity activity against P-388
84 lymphocytic leukemia cells, the induction of differentiation of human HL-60
85 promyelocytic leukemia cells toward both myelocytic and monocytic lineages, the
86 inducement of cell apoptosis in human multidrug resistant (MDR) KB-V1 cells [16].
87 However, so far the effects and molecular mechanisms of anti-cancer growth and anti-
88 invasive motility behind PA-treated human cervical cancer cells remain unknown.

89 The potentially effective plant-based products against human cervical cancer cells
90 need to be explored and identified. In the present study, we investigated whether PA
91 inhibits cell growth, migration and invasion, and further identified the precise
92 molecular mechanisms in human cervical cancer HeLa cells. The results demonstrated
93 that PA treatment inhibits cell growth, induces cell cycle arrest at G0/G1 phase through
94 the increase in p21 and p27 levels and the inhibition of cyclin D1 and Skp2 expression.
95 PA significantly suppressed TPA-induced invasive motility through deactivation of
96 ERK1/2 signaling pathway, inhibition of MMP-2 expression, and upregulation of
97 TIMP-2 level in human cervical cancer HeLa cells. This study suggested that PA
98 possesses the anticancer properties through inhibiting cell growth and invasive potential
99 of human cervical cancer cells.

100 **2. Results**

101 *2.1. PA reduces cell viability and colony formation in human cervical cancer HeLa cells*

102 We observed the effect of PA on cell viability and colony formation in human
103 HeLa cells. HeLa cells were treated with various concentrations of PA (0, 10, 20, 30,
104 40 and 50 μ M) for 24 h, and followed by MTT assay and colony formation assay
105 (Figure 1A-C). The results showed that PA possesses the effect in the inhibition of cell
106 growth in human cervical cancer HeLa cells.

107 *2.2. PA induces cell cycle arrest at G0/G1 phase in human cervical cancer HeLa cells*

108 Flow cytometry assay was performed to further confirm the effect of PA on
109 regulation of cell cycle (Figure 2A). The results showed that PA showed the effect in
110 the induction of cell cycle arrest at G0/G1 phase. The factors cyclin D1, p21, Skp2 and
111 p27 involved in cell cycle regulation were measured in human HeLa cells. PA
112 significantly inhibited the expression of cyclin D1 and Skp2 proteins, accompanied
113 with the increase of p21 and p27 protein levels (Figure 2B).

114 *2.3. PA inhibits cell migration/invasion and MMP-2 expression in human cervical* 115 *cancer HeLa cells*

116 To identify the effect of PA on cellular migration and invasion activity in human
117 HeLa cells, we treated hum HeLa cells with various concentrations of PA (0, 10, 20 and
118 30 μ M) for 24h. We found that PA significantly inhibited cellular migration and
119 invasion activity in human HeLa cells. The inhibitory effect of PA presented a dose-
120 dependent manner in the reduction of HeLa cell migration and invasion (Figure. 3A).
121 MMP-2 and MMP-9 have been reported to play a critical role in cancer cell migration
122 and invasion by contributing to the degradation of the ECM and cancer progression. To
123 identify the effect of PA on gene and protein expression of MMP-2 and -9 in human

124 cervical cancer cells, we treated hum HeLa cells with various concentrations of PA (0,
125 10, 20 and 30 μ M) for 24h, and subjected to immunoblotting assay and qRT-PCR. The
126 results showed that protein and gene levels of MMP-2 in human HeLa cells were
127 significantly reduced when exposed to PA (10 and 20 μ M) for 24h. The significant
128 reduction of MMP-2 in protein and gene by PA treatment presented a phenomenon of
129 dose-dependent manner. Furthermore, we observed the expression of TIMP-1 and -2 in
130 the levels of protein and gene. TIMP-2 was significantly upregulated in a dose-
131 dependent manner after PA treatment (10, 20 and 30 μ M) (Figure 3B, 3C).

132 *2.4. Role of ERK1/2 in PA-modified MMP-2 and TIMP-2 expression in human cervical* 133 *cancer HeLa cells*

134 To identify which signal transduction pathway(s) was involved in the mechanism
135 behind PA-regulated activity of migration and invasion in human HeLa cells, we
136 treated human HeLa with PA (10, 20 and 30 μ M). HeLa cells then were harvested for
137 immunoblotting assay to observe the activation of signaling pathways. We found that
138 PA inhibits the activity of endogenous ERK1/2 signaling pathway with no influence on
139 activation of JNK1/2 and p38 pathways (Figure 4A). To identify the role of ERK1/2
140 signaling pathway in PA-inhibited invasive motility, we applied PD98059 (specific
141 MEK1/2-ERK1/2 pathway inhibitor) to specifically blocked the activation and
142 expression ERK1/2. We found that PD98059 significantly enhanced PA-induced
143 inhibitory effect on invasive motility (Figure 4B), downregulation of MMP-2
144 expression, and upregulation of TIMP-2 in human HeLa cells (Figure 4C, 4D). The
145 results suggested that ERK1/2 signaling pathways was involved in PA-inhibited
146 invasive motility in human HeLa cells.

147 *2.5. PA inhibits TPA-induced ERK1/2 activation, MMP-2 expression and* 148 *migration/invasion in human cervical cancer HeLa cells*

149 We further examined whether PA suppressed the effect of 12-O-
150 tetradecanoylphorbol-13- acetate (TPA) on human HeLa cells. We observed that
151 TPA(50 ng/ml) significantly induced the activation of ERK1/2, JNK1/2 and p38
152 proteins in a time-dependent manner (Figure 5A). Human HeLa cells were treated with
153 various concentration of PA (0, 20 and 30 μ M) in the presence of TPA (50 ng/ml). We
154 found that PA significantly inhibited TPA increased cell invasive motility, activation
155 of ERK1/2, and expression of MMP-2 at the protein and mRNA in human HeLa cells
156 (Figure 5B-5D). These results provided that PA notably reversed the effect of TPA in
157 human cervical cancer HeLa cells.

158 **3. Discussion**

159 Plant-derived compounds are showed to be as the potential agents with many
160 anti-cancer bioactivities. Prenylated coumarins, the ethanol extracts of
161 *Peucedanum praeruptorum*, exhibits *in vitro* cytotoxic activity against
162 human cancer cell lines including HL-60, A-549, SMMC-7721, MCF-7 and SW-480
163 cells [17]. Angular pyranocoumarin extracted from *Peucedanum praeruptoruon*
164 inhibits the proliferation and induces the apoptosis in U266 cells through
165 upregulating expression of caspase-8 and -3 proteins and downregulating expression
166 of phospho-ERK, phospho-AKT proteins and the hTERT mRNA [18].
167 Pyranocoumarins from root extracts of *Peucedanum praeruptorum* Dun are showed
168 to downregulate nitric oxide (NO) production, and inhibit the efflux of drugs by
169 multidrug-resistance (MDR) proteins[19]. Praeruptorin A (PA) from
170 *Peucedanum praeruptorum* Dun shows antiproliferative and cytotoxic effects on
171 human gastric cancer SGC7901 cells. Moreover, PA enhances the inhibitory effects
172 of doxorubicin (DOX) on human SGC7901 cells. Inhibition of cell growth is higher
173 when co-treatment with PA and DOX than that with the chemotherapy agent applied

174 alone[20]. So far no study explores the effect of PA on the development/progress of
175 human cervical cancer cells. Expression change of cell cycle-regulation factors and
176 the subsequent dysregulation of cell cycle are critical steps in leading to the
177 development and progress of tumor, which are the most events founded in human
178 cancers. Overexpression of cyclin D1 and Skp2 are associated with the poor
179 prognosis in various human cancers[13,21]. Cyclin D1 plays a key intracellular
180 regulator involved in the progression of the cell cycle through G1, and contributes to
181 a worse prognosis. Skp2 acts as a oncogene and is involved in the double negative
182 feedback loops with both p21 and p27 proteins that control cell cycle entry and G1/S
183 transition [22,23]. In this study, we investigated the properties of PA in the anti-
184 proliferation and anti-metastasis, and identified the molecular mechanism of PA in
185 human cervical cancer cells. We observed that PA shows the induction in cell growth
186 inhibition and cell cycle arrest at G0/G1 phase in human cervical cancer HeLa cells.
187 PA might significantly inhibits cell proliferation and colony formation through
188 downregulation of cyclin D1 and Skp2 proteins, and upregulation of p21 and p27
189 proteins. The findings suggested that PA might exert the protective effects against
190 progression of human cervical cancer by modulating cell cycle.

191 Extracellular matrix (ECM) remodeling contributes to migration and invasion of
192 cancer cells during distant metastasis. The process in disrupting the interaction between
193 cells and ECM leads to the development of malignant tumor. Upregulation in MMPs
194 expression/activation is showed to be associated with ECM remodeling progress, tumor
195 cell invasion and metastasis. MMP activation is closely is regulated by physiological
196 inhibitor, tissue inhibitor of metalloproteinases(TIMPs). Four type of TIMP species
197 have been identified as TIMP-1, TIMP-2, TIMP-3 and TIMP-4. TIMP binds to MMP
198 in a 1:1 stoichiometric ratio. TIMPs not only directly inhibit MMPs but also form

199 complexes with MMPs to control activation and stability of MMPs. Increased
200 expression of MMP-2 and MMP-9, and decreased expression of TIMP-1 and TIMP-2
201 might serve as markers of invasive and metastatic potential of the
202 squamous cervical carcinoma (SCC) tumor [24]. TIMP-2 gene methylation is reported
203 to be the characteristic in human cervical lesions [25]. Staurosporine might induce anti-
204 tumor response in the cervical tumor microenvironment, and
205 inhibits cancer progression and metastases through suppression of MMP-1 and MMP-
206 2 [26]. HPV16E6 and E7 oncoproteins cooperate and promote the cervical
207 cancerinvasiveness by specifically upregulating MMP-2 transcription [27]. Anti-viral
208 drugs Ribavirin and Indinavir are reported to act as therapy against HPV-18
209 induced cervical cancer by decreasing MMP-2 and MMP-9 secretion [28]. MMP-2 and
210 MMP-9 are associated with the progression of cervical cancer when exposed to low
211 concentrations of arsenic trioxide and humic acid [29]. Both MMP-2 and MMP-9 play
212 the important role in cancer progression and remodeling of the ectocervix. MMP-2 and
213 MMP-9 could be used diagnostic detection for cervical lesion and cancer[30]. In this
214 study, we found that PA dramatically inhibits cell migration and invasion through
215 downregulating MMP-2 expression and upregulating TIMP-2 expression in human
216 HeLa cells. The results indicate PA as potential antimetastasis agents against human
217 cervical cancer cells.

218 Mitogen-activated protein kinases (MAPKs) participate in many biological
219 functions and cellular responses such as cell survival, proliferation, invasion and
220 apoptosis, depending on the stimuli, intensity, and duration, as well as cell types. Some
221 studies show that ERK1/2 mediates fisetin-induced apoptosis by activating caspase-
222 8/caspase-3 dependent pathways in human cervical HeLa cells [31]. ERK1/2
223 contributes to Securinine-induced cell cycle arrest and apoptosis in human HeLa

224 cells[32]. p38 MAPK mediates fisetin-suppressed urokinase plasminogen activator
225 (uPA) expression and invasion in human cervical cancer cells [33]. α -Mangostin could
226 inhibit the tumor growth of cervical cancer cells through enhancing ROS amounts to
227 activate ASK1/p38 signaling pathway and damage the integrity of mitochondria and
228 thereby induction of apoptosis in cervical cancer cells [12]. p38 MAPK kinase mediates
229 DEPTOR-regulated survival and apoptosis in human squamous cervical carcinoma
230 (SCC) tumor[34]. Activation of p38 MAPK kinase mediates Neferine-enhanced
231 antitumor effect of mitomycin-c in human HeLa cells[35]. Goniiothalamine possesses a
232 cytotoxic effect against human HeLa cells via the induction of mitochondria-mediated
233 apoptosis, associated with ER stress-induced activation of JNK1/2 [36]. In this study,
234 we attempted to identify the role of these factors including ERK1/2, p38 and JNK1/2
235 in PA-regulated expression MMPs expression, TIMPs expression, migration and
236 invasion in human HeLa cells. PA significantly suppresses endogenous activity of
237 ERK1/2 signaling pathway, but not JNK1/2 and p38 pathways. We found that PD98059
238 (specific ERK1/2 inhibitor) significantly enhanced PA-inhibited migration, invasion
239 and MMP-2 gene/protein expression, and PA-increased TIMP-2 gene/protein
240 expression in human HeLa cells. Furthermore, we observed that PA notably suppresses
241 TPA-upregulated ERK1/2 activity, MMP-2 gene/protein expression and invasive
242 motility in human HeLa cells. These findings suggested that PA exerts the strong anti-
243 cancer bioactivity against human cervical cancer cells.

244 The present results suggested PA might possess the anti-cancer capacity in
245 suppressing cell growth and invasive motility through deactivating ERK1/2 signaling
246 pathway and MMP-2 expression, and increasing TIMP-2 level. Moreover, PA
247 significantly inhibited TPA-induced invasive motility, ERK1/2 pathway activation and
248 MMP-2 expression in human cervical cancer HeLa cells. To our knowledge, this study

249 first demonstrates the effects and molecular mechanisms underlying the anti-cancer
250 potential properties of PA against human cervical cancer cells.

251 **4. Materials and Methods**

252 *4.1. Reagents*

253 A stock solution of paeruptorin A (PA) was made at a concentration of 100 mM in
254 ethanol and stored at -20 °C. Antibodies against cyclin D1, p21, Skp2, p27, MMP-2,
255 MMP-9, TIMP-1, TIMP-2, p-ERK1/2, ERK1/2, p-JNK1/2, JNK1/2, p-p38, p38 and β -
256 actin were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). The MEK1/2
257 inhibitor, PD98059 was purchased from Calbiochem (San Diego, CA). Horseradish
258 peroxidaselabeled anti-mouse and anti-rabbit secondary antibodies were obtained from
259 Promega (Madison, WI). MTT was purchased from Sigma (St. Louis, MO). All stock
260 solutions were wrapped in foil and kept at -20 °C.

261 *4.2. Cell Culture*

262 Human cervical cancer cell line, HeLa (BCRC No 60005) was obtained from the
263 Bioresources Collection and Research Center, Food Industry Research and
264 Development Institute (Hsinchu, Taiwan). HeLa cells were maintained in Dulbecco's
265 modified Eagle's medium (DMEM, GibcoInvitrogen Corporation, CA), cells were
266 supplemented with 10 % fetal bovine serum (FBS, Gibco-Invitrogen Corporation, CA)
267 and 1 % antibiotics (10,000 units/mL penicillin, 10 μ g/mL streptomycin (Invitrogen
268 Life Technologies, Carlsbad, CA) in a humidified atmosphere of 5 % CO₂ at 37 °C.

269 *4.3. Immunoblotting*

270 To isolate total proteins, cells were washed with cold PBS and resuspended in lysis
271 buffer (50 mM Tris , pH 7.5, 0.5M NaCl, 1.0 mM EDTA ,pH 7.5, 10% glycerol, 1mM
272 BME, 1% NP40) plus proteinase inhibitor cocktail and phosphatase inhibitor cocktail

273 (Roche Molecular Biochemicals). After incubation for 30 min on ice, the supernatant
274 was collected by centrifugation at 12,000 g for 15 min at 4 °C, and the protein
275 concentration was determined by the Bradford method. Sample containing equal
276 proteins (40µg) were loaded and analyzed by immunoblotting. Briefly, proteins were
277 separated by 12% SDS-PAGE and transferred onto PVDF membrane (Life
278 Technologies, Carlsbad, CA, USA). Membrane were blocked with blocking buffer (5%
279 non-fat dry milk, 20 mM Tris-HCl, pH 7.6, 150 mM NaCl, and 0.1% Tween 20) for at
280 least 1 h at room temperature. Membranes were incubated with primary antibodies in
281 the above solution on an orbit shaker at 4 °C overnight. Following primary antibody
282 incubations, membranes were incubated with horseradish peroxidase-linked secondary
283 antibodies (anti-rabbit, anti-mouse, or anti-goat IgG). Antibody-bound protein bands
284 were detected using high sensitive Immobilon Western Chemiluminescent HRP
285 Substrate (Millipore, Billerica, MA, USA), and photographed with Bio-Rad
286 Chemiluminescence Imaging System (Bio-Rad Laboratories, Inc. Hercules, CA, USA)

287 *4.4. Cell Viability Assay*

288 To determine the effect of PA on human cervical cancer HeLa cell viability, cells were
289 treated with PA and were subjected to MTT assay. The absorbance of blue formazan
290 crystals was measured at 570 nm using an enzyme-linked immunosorbent assay plate
291 reader. The quantity of the formosan product was directly proportional to the number
292 of viable cells in the culture medium. The cell viability of cells was determined
293 according to the absorbance corrected to a background reading.

294 *4.5. Colony formation assay*

295 Human cervical cancer HeLa cells were seeded into 6-well plates for 2 weeks. Colonies
296 composing more than 50 cells were stained with 0.5% crystal violet for 30 min at room

297 temperature. Triplicate independent experiments were performed.

298 *4.6. Flow Cytometric Analysis*

299 Cells were centrifuged at 800 rpm at 4 °C for 5 min, washed with ice-cold PBS
300 and stained with propidium iodide (PI) buffer (4 µg/ml PI, 1% Triton X-100, 0.5 mg/ml
301 RNase A in PBS). The cells then were analyzed using a FACS Vantage flow cytometer
302 that uses the Cellquest acquisition and analysis program (Becton Dickinson FACS
303 Calibur, San Joes, CA, USA). Cells were gated to exclude cell debris, doublets, and
304 clumps. The apoptotic cells with hypodiploid DNA content were detected in the sub-
305 G1 region.

306 *4.7. Migration and Invasion Assay*

307 Cell migration and invasion assays were performed using the 24-well modified Boyden
308 chambers containing membrane filter inserts with 8-µm pores (Corning Incorporated
309 Life Sciences, Tewksbury, MA, USA). Membrane filter inserts were pre-coated with
310 Matrigel Matrix (Cat. No.354230; Corning Incorporated Life Sciences, Tewksbury, MA,
311 USA) for invasion assay. The lower compartment was filled with DMEM containing
312 10% FCS. Cells were placed in the upper part of the Boyden chamber containing serum-
313 free medium and incubated for 16~24 h. The migratory and invasive phenotypes were
314 determined by counting the cells that migrated to the lower side of the filter with
315 microscopy at 100x and 200x magnification, respectively. The fourth fields were
316 counted for each filter, and each sample was assayed in triplicate.

317 *4.8. Reverse Transcription and Real-Time PCR Assay*

318 Total RNA was isolated from cultured cells. The cells were homogenized in RNA
319 lysis/binding buffer. The High Pure RNA Tissue Kit (Roche Applied Science,
320 Mannheim, Germany) was used for RNA extraction. The standards reverse

321 transcription and real-time PCR protocol was used in this study. For reverse
322 transcription, the samples were incubated at 25 °C for 10 min, real-time PCR was
323 initiated with a hot start (10 min at 95°C, 1 cycle), the samples were then subjected to
324 40 cycles at 95 °C for 15 sec and 60 °C for 1 min. Data was analysed by StepOne real-
325 time PCR system (Applied Biosystems, Foster City, California, USA). Primers were as
326 follows: human MMP-2 forward primer 5'TGGCAAGTACGGCTTCTGTC-3',
327 reverse primer 5'TTCTTGTCGCGGTCGTA
328 GTC-3'; human MMP-9 forward primer 5'-CCTGCCAGTTTCC ATTCATC-3';
329 reverse primer 5'-GCCATTCACGTCGTCCTTAT-3'; human TIMP-1 forward primer
330 5'-CAGTAGAATGGGAGAGTC-3', human TIMP-1 reverse primer 5'-GGTGATG
331 AAGCAGCCCAG-3'; human TIMP-2 forward primer 5'-GGCGTTTTGCAATGCA
332 GATGTAG-3', human TIMP-2 reverse primer 5'-CACAGGAGCCGTCACCTTCTCT
333 TG-3'; human β -actin forward primer 5'-GCACTCTTCCAGCCTTCCTTCC-3'
334 reverse primer 5'-TCACCTTCACCGTTCC AGTTTTT-3' (MISSION BIOTECH,
335 Taipei, Taiwan). Relative gene expression was obtained after normalization with
336 endogenous β -actin and determination of the difference in threshold cycle (Ct) between
337 treated and untreated cells using $2^{-\Delta\Delta C_t}$ method.

338 4.9. Statistical Analysis

339 Each experiment was repeated at least three times. Results were presented as the mean
340 \pm SE, and statistical comparisons were made using the Student's *t* test. Significance was
341 defined at the $p < 0.05$ or 0.01 levels.

342 CONFLICT OF INTEREST

343 The authors do not have any conflict of interest about this paper.

344 ACKNOWLEDGEMENT

345 This study was supported by Chung-Kang Branch, Cheng-Ching General Hospital

346 Research Fund (grant number CH10600205A).

347 **Author Contributions:** Min-Hua Wu, Yi-Hsien Hsieh and Chung-Jung Liu designed
348 the experiments and research project. Chia-Liang Lin and Shun-Fa Yang performed the
349 experiments and analyzed the data. Hui-Ling Chiou participated in the discussion. Yi-
350 Hsien Hsieh and Chung-Jung Liu wrote the paper.

351 REFERENCES

- 352 1. Eskander, R.N.; Tewari, K.S. Chemotherapy in the treatment of metastatic,
353 persistent, and recurrent cervical cancer. *Curr Opin Obstet Gynecol* 2014, 26, 314-
354 321.
- 355 2. Takeuchi, H.; Kitajima, M.; Kitagawa, Y. Sentinel lymph node as a target of
356 molecular diagnosis of lymphatic micrometastasis and local immunoresponse to
357 malignant cells. *Cancer Sci* 2008, 99, 441-450.
- 358 3. Yamamoto, K.; Yoshikawa, H.; Shiromizu, K.; Saito, T.; Kuzuya, K.; Tsunematsu,
359 R.; Kamura, T. Pulmonary metastasectomy for uterine cervical cancer: a
360 multivariate analysis. *Ann Thorac Surg.* 2004, 77, 1179-1182.
- 361 4. Thanappapasr, D.; Nartthanarung, A.; Likittanasombut, P, Na.; Ayudhya, N.I.;
362 Charakorn, C.; Udomsubpayakul, U.; Subhadarbandhu, T.; Wilailak, S. Bone
363 metastasis in cervical cancer patients over a 10-year period. *Int J Gynecol Cancer.*
364 2010, 20, 373-378.
- 365 5. Park, J.Y.; Lim, M. C.; Lim, S. Y.; Bae, J.M.; Yoo, C. W.; Seo, S. S.; Kang, S.; Park,
366 S.Y. Port-site and liver metastases after laparoscopic pelvic and para-aortic lymph
367 node dissection for surgical staging of locally advanced cervical cancer. *Int J*
368 *Gynecol Cancer.* 2008, 18, 176-180.
- 369 6. Kanthan, R.; Senger, J. L.; Diudea, D.; Kanthan, S. A review of duodenal metastases
370 from squamous cell carcinoma of the cervix presenting as an upper gastrointestinal

- 371 bleed. *World J Surg Oncol.* 2011, 9, 113.
- 372 7. Liotta, L.A.; Stetler-Stevenson, W. G. Tumor invasion and metastasis: an imbalance
373 of positive and negative regulation. *Cancer Res.* 1991, 51, 5054s-5059s.
- 374 8. Yoon, W. H.; Jung, Y.J.; Kim, T. D.; Li, G.; Park, B.J.; Kim, J.Y.; Lee, Y.C.; Kim, J.
375 M.; Park, J. I.; Park, H. D.; No, Z. S.; Lim, K.; Hwang, B. D.; Kim, Y. S. Gabexate
376 mesilate inhibits colon cancer growth, invasion, and metastasis by reducing matrix
377 metalloproteinases and angiogenesis. *Clin Cancer Res.* 2004, 10, 4517-4526.
- 378 9. Coussens, L.M.; Fingleton, B.; Matrisian, L. M. Matrix metalloproteinase inhibitors
379 and cancer: trials and tribulations. *Science.* 2002, 295, 2387-2392.
- 380 10. Ellerbroek, S.M.; Stack, M.S. Membrane associated matrix metalloproteinases in
381 metastasis. *Bioessays.* 1999, 21, 940-949.
- 382 11. Tsai, S.J.; Hwang, J. M.; Hsieh, S. C.; Ying, T. H.; Hsieh, Y. H. Overexpression of
383 myeloid zinc finger 1 suppresses matrix metalloproteinase-2 expression and
384 reduces invasiveness of SiHa human cervical cancer cells. *Biochem Biophys Res*
385 *Commun.* 2012, 425, 462-467.
- 386 12. Lee, C. H.; Ying, T.H.; Chiou, H. L.; Hsieh, S. C.; Wen, S. H.; Chou, R. H.; Hsieh,
387 Y. H. Alpha-mangostin induces apoptosis through activation of reactive oxygen
388 species and ASK1/p38 signaling pathway in cervical cancer cells. *Oncotarget*, 2017,
389 8, 47425-47439.
- 390 13. Ying, T.H.; Lee, C. H.; Chiou, H. L.; Yang, S. F.; Lin, C. L.; Hung, C. H.; Tsai, J.P.;
391 Hsieh, Y.H. Knockdown of Pentraxin 3 suppresses tumorigenicity and metastasis of
392 human cervical cancer cells. *Sci Rep.* 2016, 6, 29385.
- 393 14. Gomez, D, E.; Alonso, D. F.; Yoshiji, H.; Thorgeirsson, U. P. Tissue inhibitors of
394 metalloproteinases: structure, regulation and biological functions. *Eur J Cell Biol.*
395 1997,74, 111-122.

- 396 15. Kma, L. Roles of plant extracts and constituents in cervical cancer therapy. *Asian*
397 *Pac J Cancer Prev.* 2013, 14, 3429-3436.
- 398 16. Sarkhail, P. Traditional uses, phytochemistry and pharmacological properties of the
399 genus *Peucedanum*: a review. *J Ethnopharmacol.* 2014, 156, 235-270.
- 400 17. Li, X.M.; Jiang, X. J.; Yang, K.; Wang, L. X.; Wen, S. Z.; Wang, F. Prenylated
401 Coumarins from *Heracleum stenopterum*, *Peucedanum praeruptorum*, *Clausena*
402 *lansium*, and *Murraya paniculata*. *Nat Prod Bioprospect.* 2016, 6, 233-237.
- 403 18. Yu, Q.; Ma, L.; Shen, Y.; Zhai, W.; Zhou, Y. [Effect of angular pyranocoumarin
404 isolated from *peucedanum praeruptorum* on the proliferation and apoptosis of U266
405 cells]. *Zhonghua Xue Ye Xue Za Zhi.* 2015, 36, 937-941.
- 406 19. Lee, J.; Lee, Y. J.; Kim, J.; Bang, O. S. Pyranocoumarins from Root Extracts of
407 *Peucedanum praeruptorum* Dunn with Multidrug Resistance Reversal and Anti-
408 Inflammatory Activities. *Molecules.* 2015, 20, 20967-20978.
- 409 20. Liang, T.; Yue, W.; Li, Q. Chemopreventive effects of *Peucedanum praeruptorum*
410 DUNN and its major constituents on SGC7901 gastric cancer cells. *Molecules.*
411 2010, 15, 8060-8071.
- 412 21. Chen, T. P.; Chen, C. M.; Chang, H. W.; Wang, J. S.; Chang, W. C.; Hsu, S. I.; Cho,
413 C. L. Increased expression of SKP2 and phospho-MAPK/ERK1/2 and decreased
414 expression of p27 during tumor progression of cervical neoplasms. *Gynecol Oncol.*
415 2007, 104: 516-523.
- 416 22. Barr, A.R.; Heldt, F. S.; Zhang, T.; Bakal, C.; Novak, B. A Dynamical Framework
417 for the All-or-None G1/S Transition. *Cell Syst.* 2016. 2. 27-37.
- 418 23. Barr, A. R.; Cooper, S.; Heldt, F. S.; Butera, F.; Stoy, H.; Mansfeld, J.; Novák, B.;
419 Bakal, C. DNA damage during S-phase mediates the proliferation-quiescence
420 decision in the subsequent G1 via p21 expression. *Nat Commun.* 2017, 8, 14728.

- 421 24. Solovsmall, u. CNI.; Timoshenko, O. S.; Gureeva, T. A.; Kugaevskaya, E. V.
422 [Matrix metalloproteinases and their endogenous regulators in squamous cervical
423 carcinoma (review of the own data)]. *Biomed Khim*, 2015, 61, 694-704.
- 424 25. Furtado, Y.; Almeida, G.; Silveira, F. A.; Silva, K. S.; Maldonado, P. do.; Val, I. C.;
425 Cavalcanti, S.; L, M. A.; Carvalho, Mda. G. TIMP-2 gene methylation in cervical
426 precursor and invasive lesions. *Exp Mol Pathol*. 2015, 98, 119-123.
- 427 26. Yadav, S. S.; Prasad, C. B.; Prasad, S. B.; Pandey, L. K.; Singh, S.; Pradhan, S.;
428 Narayan, G. Anti-tumor activity of staurosporine in the tumor microenvironment of
429 cervical cancer: An in vitro study. *Life Sci*. 2015, 133, 21-28.
- 430 27. Kaewprag, J.; Umnajvijit, W.; Ngamkham, J.; Ponglikitmongkol, M. HPV16
431 oncoproteins promote cervical cancer invasiveness by upregulating specific matrix
432 metalloproteinases. *PLoS One*. 2013, 8, e71611.
- 433 28. Sharma, S.; Baksi, R.; Agarwal, M. Repositioning of anti-viral drugs as therapy for
434 cervical cancer. *Pharmacol Rep*. 2016, 68, 983-989.
- 435 29. Tsai, M.L.; Yen, C. C.; Lu, F. J.; Ting, H. C.; Chang, H. R. Environmentally relevant
436 concentration of arsenic trioxide and humic acid promoted tumor progression of
437 human cervical cancer cells: In vivo and in vitro studies. *Environ Toxicol*. 2016, 31,
438 1121-1132.
- 439 30. Ghosh, A.; Moirangthem, A.; Dalui, R.; Ghosh, T.; Bandyopadhyay, A.; Dasgupta,
440 A.; Banerjee, U.; Jana, N.; Basu, A. Expression of matrix metalloproteinase-2 and
441 9 in cervical intraepithelial neoplasia and cervical carcinoma among different age
442 groups of premenopausal and postmenopausal women. *J Cancer Res Clin Oncol*.
443 2014, 140, 1585-1593.
- 444 31. Ying, T. H.; Yang, S. F.; Tsai, S. J.; Hsieh, S. C.; Huang, Y. C.; Bau, D. T.; Hsieh, Y.
445 H. Fisetin induces apoptosis in human cervical cancer HeLa cells through ERK1/2-

- 446 mediated activation of caspase-8-/caspase-3-dependent pathway. *Arch Toxicol.*
447 2012, 86, 263-273.
- 448 32. Stefanowicz-Hajduk, J.; Sparzak-Stefanowska, B.; Krauze-Baranowska, M.;
449 Ochocka, J. R. Securinine from *Phyllanthus glaucus* Induces Cell Cycle Arrest and
450 Apoptosis in Human Cervical Cancer HeLa Cells. *PLoS One.* 2016, 11, e0165372.
- 451 33. Chou, R.H.; Hsieh, S. C.; Yu, Y. L.; Huang, M. H.; Huang, Y. C.; Hsieh, Y. H. Fisetin
452 inhibits migration and invasion of human cervical cancer cells by down-regulating
453 urokinase plasminogen activator expression through suppressing the p38 MAPK-
454 dependent NF-kappaB signaling pathway. *PLoS One.* 2013, 8, e71983.
- 455 34. Srinivas, K. P.; Viji, R.; Dan, V. M.; Sajitha, I. S.; Prakash, R.; Rahul, P. V.;
456 Santhoshkumar, T. R.; Lakshmi, S.; Pillai, M. R. DEPTOR promotes survival of
457 cervical squamous cell carcinoma cells and its silencing induces apoptosis through
458 downregulating PI3K/AKT and by up-regulating p38 MAP kinase. *Oncotarget.*
459 2016, 7, 24154-24171.
- 460 35. Eid, W.; Abdel-Rehim, W. Neferine Enhances the Antitumor Effect of Mitomycin-
461 C in Hela Cells Through the Activation of p38-MAPK Pathway. *J Cell Biochem.*
462 2017, 118, 3472-3479.
- 463 36. Sophonnithiprasert, T.; Mahabusarakam, W.; Nakamura, Y.; Watanapokasin, R.
464 Goniotalamin induces mitochondria-mediated apoptosis associated with
465 endoplasmic reticulum stress-induced activation of JNK in HeLa cells. *Oncol Lett.*
466 2017,13, 119-128.

467 **Figure Legend**

468 **Fig. 1. The effect of PA on cellular growth in human cervical cancer HeLa cells (A)**
469 Structure of Praeruptorin A. **(B)** Cell viability of HeLa cells treated with various
470 concentrations of PA (0, 10, 20, 30, 40 and 50 μ M) for 24h were measured by MTT

471 assay. **(C)** Colony formation of HeLa cells treated with various concentrations of PA (0,
472 10, 20 and 30 μM) was measured. *, $p < 0.05$ versus control (line 1); **, $p < 0.01$ versus
473 control, (mean \pm SE, n = 3).


474 **Fig. 2. The effect of PA on cell cycle regulation in human HeLa cells** **(A)** Cell cycle
475 of HeLa cells treated with various concentrations of PA (0, 10, 20 and 30 μM) was
476 measured by flow cytometry. (mean \pm SE, n = 3). **(B)** The related proteins of cell cycle
477 regulation were measured in HeLa cells treated with various concentrations of PA (0,
478 10, 20 and 30 μM) for 24h. *, $p < 0.05$ versus control; **, $p < 0.01$ versus control, (mean
479 \pm SE, n = 3).

480 **Fig. 3. The effect of PA on cell migration / invasion, and protein expression of**
481 **MMPs and TIMPs in human cervical cancer HeLa cells** **(A)** HeLa cells were treated
482 with various concentrations of PA (0, 10, 20 and 30 μM) for 24h, then followed by
483 measuring the capacity of cell migration and invasion. **(B)** HeLa cells were treated with
484 various concentrations of PA (0, 10, 20 and 30 μM) for 24h. Cells were then harvested
485 for detection of protein and gene expression by western blotting and **(C)** qRT-PCR. *,
486 $p < 0.05$ versus control (line 1); **, $p < 0.01$ versus control, (mean \pm SE, n = 3).

487 **Fig. 4. The role ERK1/2 in PA-regulated MMP-2 and TIMP-2 expression in human**
488 **HeLa cells** **(A)** HeLa cells were treated with various concentrations of PA (0, 10, 20
489 and 30 μM) for 1 hr. Cells were harvested and lysed at the indicated dose points. Target
490 protein level was measured by western blotting with specific antibodies. **(B)** HeLa cells
491 were treated with/without PA in the presence of PD98059 (ERK1/2 specific inhibitor)
492 for 24h. Migration and invasion in human HeLa cells were measured. **(C, D)** Effect of
493 PA (20 μM) and PD98059 (20 μM) on protein and gene expression in MMP-2 and
494 TIMP-2 were measured by immunoblotting assay and qRT-PCR. **, $p < 0.01$ versus
495 control; #, $p < 0.05$ versus only PA treatment (mean \pm SE, n = 3).

496 **Fig. 5. The inhibitory effect of PA on TPA-induced ERK1/2 activation, MMP-2**
497 **expression and migration/invasion in human cervical cancer HeLa cells (A)** HeLa
498 cells were treated with/without PA (20 μ M) in the presence of TPA (50ng/ml) for 30,
499 60, 90 and 120 min. Cells were harvested and lysed at the indicated time points. Target
500 protein level was measured by western blotting with specific antibodies. **(B)** HeLa cells
501 were treated with/without various concentrations of PA (20 μ M) in the presence of TPA
502 (50ng/ml) for 24hrs. Migration and invasion of human HeLa cells then were measured.
503 **(C, D)** HeLa cells were treated with/without various concentrations of PA (0, 10, 20
504 and 30 μ M) in the presence of TPA(50 ng/ml) for 1 hr to detect phospho-ERK1/2
505 protein, and for 24 hrs to detect MMP-2 protein and gene levels. **, $p < 0.01$ versus
506 control (line1); #, $p < 0.05$ versus only TPA treatment (mean \pm SE, n = 3).



1
2 **Fig.1**
3



4

1 **Fig. 2**


2

A**B**


3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34

1
2
3

Fig. 3

4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24


1
2 **Fig. 4**
3



4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

1
2
3

Fig. 5



4
5